glp-1 news today november 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Weight Loss Drug Enforcement
Description
Tau pathology in neurodegenerative disease: Disease mechanisms and therapeutic avenues
[DOI] [PMC free article] [PubMed] [Google Scholar] 175.Nunn E, et al
The SCT receptor seems to drive many of the side effects seen in other non-selective amylin agonists cough cagrilintide cough The shade in this slide is not subtle
Paleo and keto both cut processed foods, but they work very differently
Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis
Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose
